The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Research output: Contribution to journalJournal articleResearchpeer-review

Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.
Original languageEnglish
Issue number7
Pages (from-to)1765-70
Number of pages6
Publication statusPublished - 1 Jul 2010

    Research areas

  • Adult, Analysis of Variance, Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucose Clamp Technique, Humans, Insulin, Male, Middle Aged, Time Factors, Treatment Outcome

ID: 33940158